Dermatologic Adverse Events Associated with T-Cell Engager Therapy

Area of Science:

• Oncology
• Immunotherapy
• Dermatology

Background:

• T-cell engager therapies are a rapidly expanding class of anticancer immunotherapy.
• Distinct dermatologic adverse events are increasingly recognized across these agents.
• Understanding these toxicities is crucial for clinical management.

Purpose of the Study:

• To review the spectrum of dermatologic adverse events associated with T-cell engager therapies.
• To highlight agent-specific and mechanistically linked cutaneous toxicities.
• To inform dermatologists on managing these side effects.

Main Methods:

• Review of emerging literature on T-cell engager therapies and their dermatologic toxicities.
• Analysis of reported adverse events, focusing on specific agents like tebentafusp and talquetamab.
• Categorization of toxicities based on agent targets and mechanisms.

Main Results:

• Tebentafusp and talquetamab show high rates of dermatologic toxicity due to on-target, off-tumor effects.
• Tebentafusp commonly causes diffuse, photodistributed erythematous eruptions.
• Talquetamab presents with unique cutaneous, nail, and oral toxicities linked to its target.
• Other agents like blinatumomab and CD20-directed therapies are associated with various rashes.
• Most skin toxicities are manageable with standard dermatologic treatments.

Conclusions:

• T-cell engager therapies present a range of predictable dermatologic adverse events.
• Agent-specific patterns of skin toxicity are linked to their mechanisms of action.
• Dermatologists play a vital role in managing these side effects, ensuring treatment continuity.